| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
179,400,000 |
| Market
Cap: |
227.84(M) |
| Last
Volume: |
2,211,986 |
Avg
Vol: |
2,301,679 |
| 52
Week Range: |
$0.449 - $1.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
86,265 |
122,918 |
235,260 |
541,068 |
| Total Sell Value |
$152,594 |
$177,518 |
$247,417 |
$1,284,611 |
| Total People Sold |
4 |
4 |
7 |
10 |
| Total Sell Transactions |
4 |
7 |
16 |
37 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Labrucherie Gil M |
SVP, COO & CFO |
• – – |
2022-05-16 |
4 |
S |
$3.95 |
$68,920 |
D/D |
(17,448) |
312,905 |
|
21% |
|
| Robin Howard W |
President & CEO |
• • – |
2022-05-16 |
4 |
S |
$3.95 |
$144,290 |
D/D |
(36,529) |
620,941 |
|
21% |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2022-05-16 |
4 |
S |
$3.95 |
$23,072 |
D/D |
(5,841) |
170,427 |
|
21% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2022-05-16 |
4 |
S |
$3.95 |
$85,608 |
D/D |
(21,673) |
276,399 |
|
21% |
|
| Northcott John |
SVP & Chief Commercial Officer |
• – – |
2022-05-16 |
4 |
S |
$3.95 |
$18,138 |
D/D |
(4,592) |
223,210 |
|
21% |
|
| Labrucherie Gil M |
SVP, COO & CFO |
• – – |
2022-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
28,750 |
330,353 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2022-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
68,450 |
657,470 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2022-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,950 |
176,268 |
|
- |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2022-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
23,950 |
298,072 |
|
- |
|
| Wilson Mark Andrew |
SVP & General Counsel |
• – – |
2022-02-16 |
4 |
S |
$10.95 |
$40,088 |
D/D |
(3,661) |
121,075 |
|
64% |
|
| Labrucherie Gil M |
SVP, COO & CFO |
• – – |
2022-02-16 |
4 |
S |
$10.95 |
$82,990 |
D/D |
(7,579) |
301,603 |
|
64% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2022-02-16 |
4 |
S |
$10.95 |
$119,486 |
D/D |
(10,912) |
274,122 |
|
64% |
|
| Northcott John |
SVP & Chief Commercial Officer |
• – – |
2022-02-16 |
4 |
S |
$10.95 |
$53,129 |
D/D |
(4,852) |
227,802 |
|
64% |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2022-02-16 |
4 |
S |
$10.95 |
$25,875 |
D/D |
(2,363) |
165,318 |
|
64% |
|
| Robin Howard W |
President & CEO |
• • – |
2022-02-16 |
4 |
S |
$10.95 |
$136,656 |
D/D |
(12,480) |
589,020 |
|
64% |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2021-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
21,200 |
167,681 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2021-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
126,050 |
601,500 |
|
- |
|
| Labrucherie Gil M |
SVP, COO & CFO |
• – – |
2021-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
52,950 |
309,182 |
|
- |
|
| Northcott John |
SVP & Chief Commercial Officer |
• – – |
2021-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
37,800 |
232,654 |
|
- |
|
| Wilson Mark Andrew |
SVP & General Counsel |
• – – |
2021-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
37,800 |
124,736 |
|
- |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2021-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
52,950 |
285,034 |
|
- |
|
| Labrucherie Gil M |
SVP, COO & CFO |
• – – |
2021-11-18 |
4 |
AS |
$12.69 |
$38,070 |
D/D |
(3,000) |
256,682 |
|
-52% |
|
| Labrucherie Gil M |
SVP, COO & CFO |
• – – |
2021-11-16 |
4 |
AS |
$13.16 |
$278,321 |
D/D |
(21,149) |
259,682 |
|
-58% |
|
| Wilson Mark Andrew |
SVP & General Counsel |
• – – |
2021-11-16 |
4 |
S |
$13.16 |
$86,382 |
D/D |
(6,564) |
86,436 |
|
58% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2021-11-16 |
4 |
S |
$13.16 |
$274,636 |
D/D |
(20,869) |
232,084 |
|
58% |
|
913 Records found
|
|
Page 3 of 37 |
|
|
0.01 (0.79%) 
